Good
Mostly Aligned
Patient Risk:
Low
Summary
Most claims are about cost/coverage and general mechanism/label-like indication. Indication claims are largely consistent with the provided label excerpts, but the response includes an extra indication phrasing for “maintenance treatment” that omits HRD/gBRCA companion diagnostic selection details. Multiple mechanistic claims (PARP/DNA repair) are consistent with the provided mechanism excerpt. Manufacturer information is not supported by the provided label excerpts. Several economic/payment claims are not addressed in the provided label excerpts and are therefore unsupported for on-label alignment.
Category Scores
Accurate Statements
ZEJULA is a poly (ADP-ribose) polymerase (PARP) inhibitor.
12.1 Mechanism of Action: Niraparib is an inhibitor of PARP enzymes.
PARP enzymes are involved in DNA repair.
12.1 Mechanism of Action: PARP-1 and PARP-2 play a role in DNA repair.
ZEJULA is approved for maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer in response to first-line or later-line platinum-based chemotherapy.
1.1 First-Line Maintenance Treatment of HRD-Positive Advanced Ovarian Cancer (maintenance after first-line platinum-based chemotherapy). Note: provided label excerpt does not describe “later-line” in the excerpt.
ZEJULA is indicated for adult patients with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response to platinum-based chemotherapy.
1.2 Maintenance Treatment of Recurrent Germline BRCA-Mutated Ovarian Cancer: maintenance for adult patients in complete or partial response to platinum-based chemotherapy.
Unsupported Statements
ZEJULA (niraparib) cost varies based on insurance coverage, pharmacy, and geographic location.
Not supported by the provided FDA label excerpts (no pricing/insurance coverage statements in excerpts).
Without insurance, the list price for a 30-day supply of ZEJULA can be substantial, often exceeding $10,000.
Not supported by the provided FDA label excerpts (no pricing data in excerpts).
Patient assistance programs and co-pay cards may significantly reduce out-of-pocket expenses for eligible individuals.
Not supported by the provided FDA label excerpts.
The manufacturer offers a ZEJULA Savings Card that can lower co-pays for commercially insured patients.
Not supported by the provided FDA label excerpts.
For eligible commercially insured patients, the ZEJULA Savings Card may reduce monthly cost to as little as $0.
Not supported by the provided FDA label excerpts.
Eligibility criteria apply for the ZEJULA Savings Card.
Not supported by the provided FDA label excerpts.
For commercially insured patients utilizing savings programs, out-of-pocket cost for ZEJULA can be as low as $0 per month.
Not supported by the provided FDA label excerpts.
For uninsured individuals or those with plans not covering ZEJULA adequately, the cost can reflect the full list price.
Not supported by the provided FDA label excerpts.
Many insurance plans cover ZEJULA.
Not supported by the provided FDA label excerpts.
Coverage levels and co-payment amounts for ZEJULA can differ among insurance plans.
Not supported by the provided FDA label excerpts.
Insurance may involve co-insurance or deductible requirements for ZEJULA.
Not supported by the provided FDA label excerpts.
ZEJULA is manufactured by GSK plc.
Manufacturer identity is not supported by the provided FDA label excerpts.
Contradictions
Important Omissions
For the first-line HRD-positive maintenance indication, selection requires HRD status defined by deleterious/suspected deleterious BRCA mutation and/or genomic instability, and selection is based on an FDA-authorized companion diagnostic.
Importance:
Moderate
For the recurrent germline BRCA-mutated maintenance indication, selection is based on deleterious/suspected deleterious germline BRCA mutations and an FDA-authorized companion diagnostic.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response primarily contains pricing/coverage statements not addressed in label excerpts and general mechanism/indication statements. It does not include label-restricted dosing, contraindications, or safety warnings. However, indication phrasing omits companion diagnostic/HRD/gBRCA selection detail, which is relevant to correct labeled use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Multiple non-label-supported claims about cost, savings cards, and insurance coverage; and omission of companion diagnostic/HRD-gBRCA selection requirements from the labeled indications.
Suggested Improvement
Limit claims to what is in the provided label excerpts (e.g., labeled maintenance indications with the required biomarker/companion diagnostic selection language, and mechanism of action). Remove or qualify pricing/insurance/savings-card assertions as they are not supported by the provided FDA labeling excerpts.